Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Background: Developing countries have an estimate of ten times more approved biosimilars than developed countries. This disparity demands the need of an objective regulation that incorporates health policies according to the technological and economical capabilities of each country. One of the chall...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mendoza-Macedo,Karina, Romero-Díaz,Alexis J, Miranda-Hernández,Mariana P, Campos-García,Víctor R, Ramírez-Ibañez,Nancy D, Juárez-Bayardo,L. Carmina, Moreno-Duran,Karen, Cedillo-Robles,Miriam S, Pérez,Nestor O, Jung-Cook,Helgi, Flores-Ortiz,Luis F, Medina-Rivero,Emilio
Lenguaje:	English
Publicado:	Pontificia Universidad Católica de Valparaíso 2016
Materias:	Bio therapeutic Comparability Critical quality attributes Developing countries Generics Health policies High quality biosimilars Regulation
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582016000600010
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Ejemplares similares